Eledon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Planned global Phase 3 LEGACY trial of tegoprubart in kidney transplantation remains on track to initiate in Q4 2026FDA cleared the Company’s IND application for a planned registrational path study of tegoprubart in islet cell transplantation for patients with type 1 diabetesFDA Fast Track designat…